Sulfateq is happy to announce that a new scientific manuscript detailing the efficacy of SUL-151 to mitigate the development of Chronic Obstructive Pulmonary Disease (COPD), was recently published in the International Journal of Molecular Sciences. This manuscript addresses the protective effects of SUL-151 in a smoke-induced Chronic Obstructive Pulmonary Disease (COPD) mouse model. COPD is a chronic inflammation of the lungs resulting in shortness of breath and impediment of breathing. It well known that cigarette smoke is one of the major causes of COPD by inducing chronic inflammation and mitochondrial dysfunction in the lung tissue. Lei Wang, Dr. Saskia Braber and Prof. Dr. Gert Folkerts from the department of Pharmacy at Utrecht University investigated both the therapeutic and prophylactic efficacy of SUL-151, and reported improved outcomes of both treatment strategies.
Increased pulmonary inflammation and mitochondrial dysfunction are inhibited by SUL-151
In the respective study, two treatment regimens were used. First, a prophylactic study design in which the mice were treated with vehicle, SUL-151 or budesonide daily for 5 days prior to exposure to cigarette smoke. Budesonide, as standard COPD treatment, was included in the study to assess the effectiveness of SUL-151. Second, a therapeutic study design in which the mice were first exposed to cigarette smoke for 5 days without treatment, after which 5 days of exposure to cigarette smoke was combined with treatment. The study data shows that both prophylactic and therapeutic treatment with SUL-151 significantly reduces cigarette smoke-induced airway neutrophilia, while budesonide showed no therapeutic effect. Furthermore, treatment with SUL-151 normalized mitochondrial dysfunction induced by cigarette smoke exposure. The authors conclude that SUL-151 shows great potential as new therapeutic for COPD.
The new publication is available through this link, would you like to receive more information about our compounds or discuss possibilities? Please contact us, we are happy to answer your inquiry!